Actively Recruiting
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-04-23
71
Participants Needed
8
Research Sites
154 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
S
Seagen Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatments for their disease. BV is a type of drug called an antibody-drug conjugate (ADC). ADCs are a substance made up of a monoclonal antibody chemically linked to a drug. Antibodies are proteins made by the immune system to fight infections and other possible harms to the body. The monoclonal antibody binds to specific proteins or receptors found on certain types of cells, including cancer cells. The linked drug enters these cells and kills them without harming other cells. Researchers think BV may be an effective treatment for this type of cancer because the drug targets cells that have CD30, which play a role in cancer cell growth. By destroying these cells, BV may help slow or stop the growth of the cancer. AVD (doxorubicin, vinblastine, and dacarbazine) is a treatment regimen that works by stopping the growth of cancer cells, either by killing the cells or by stopping them from dividing. The researchers think that BV in combination with AVD may work better than AVD alone to slow or stop the growth of the cancer.
CONDITIONS
Official Title
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of classical, CD30-positive Hodgkin lymphoma confirmed by biopsy
- Ann Arbor stage I or II disease confirmed by FDG-PET/CT
- Bulky disease defined as lymph node mass with diameter 7.0 cm or larger on CT
- Age 18 years or older
- ECOG performance status of 2 or less
- Women of childbearing age must use accepted birth control during treatment
- Men must consistently use accepted contraception during treatment
You will not qualify if you...
- Prior systemic or radiation therapy for Hodgkin lymphoma (except corticosteroids)
- Cardiac ejection fraction less than 50% by echocardiogram
- Platelet count 75,000/μL or lower
- Hemoglobin level 7.0 mg/dL or lower
- Absolute neutrophil count 1.0 K/μL or lower
- Creatinine clearance less than 30 mL/min
- Liver enzyme levels more than 3 times upper limit of normal (except higher limits with Gilbert's disease)
- Total bilirubin 1.5 times or higher than upper limit of normal (with exceptions for Gilbert's disease)
- Pre-existing peripheral neuropathy of grade 2 or higher
- Known pregnancy or breastfeeding
- Active hepatitis B or C viral infection (with specific exceptions if viral DNA is negative)
- Other active malignancy requiring treatment in past 2 years except certain skin, cervical, breast, or prostate cancers
- Autoimmune conditions needing active systemic immunosuppressive therapy
- Medical illness making participation inappropriate as judged by physician
- HIV-positive patients must be on appropriate antiretroviral therapy without prohibited agents
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
University of Miami
Miami, Florida, United States, 33136
Not Yet Recruiting
2
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
3
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
4
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
5
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
Commack, New York, United States, 11725
Actively Recruiting
6
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
7
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065
Actively Recruiting
8
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
R
Robert Stuver, MD
CONTACT
A
Alison Moskowitz, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here